Congratulations to the following faculty members for receiving these sponsored research awards:
Sponsored Research
Michael Gunn of Cardiology has received an award (1R21-AI180397-01A1) from the National Institutes of Health for a project entitled "Development of Diagnostic Antibodies for Acute and Chronic Chagas Disease." Total funding will be $449,408.
Yubin Kang of Cell Therapy has received an award from the Cancer Research Institute for a project entitled "Targeting sphingosine kinase 2 to enhance CAR T-cell therapy efficacy in multiple myeloma." Total funding will be $300,000.
William Yancy of General Internal Medicine has received a sub-award (HMC-2023C2-22427) through the University of Iowa for a project entitled "Improving High Blood Pressure in Rural, Older Adults - The SMBP Study." Total funding will be $346,730.
Laura Alder of Oncology has received an award from the Lung Cancer Initiative of North Carolina for a project entitled "CNS PATTERN: CNS Progression After Targeted Therapy and Effect of Radiation in NSCLC." Total funding will be $24,630.
Daniel George of Oncology has received an award from the American Cancer Society, Inc. for a project entitled "ACS Professor Award - Race based cohort trials to improve outcomes for Black men." Total funding will be $400,000.
Aparna Swaminathan of Pulmonary has received a sub-award (RI-VUMC-01-MC) through the Vanderbilt University Medical Center for a project entitled "Enhancing Capacity of the PCORnet® Common Data Model to Support PCORI Priorities in Patient-Centered CER." Total funding will be $85,000.
Industry Sponsored Clinical Trials
William Jones of Cardiology has received an award from Novartis Pharmaceuticals Corporation for a project entitled "Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORIAN-INTERVENTION)." Total funding will be $297,830.
Jonathan Piccini of Cardiology has received an award from American Heart Association for a project entitled "GWTG Inpatient Data Analysis Center." Total funding will be $124,993.
Jennifer Rymer of Cardiology has received an award from St. Jude Medical Business Services Inc. for a project entitled "Patient Preferences in the Management of Intermittent Claudication." Total funding will be $157,762.
Nishant Shah of Cardiology has received an award from St. Jude Medical Business Services Inc. for a project entitled "The Impact of Optimal Medical Therapy on Both Limb and Cardiovascular Events in Patients with Chronic Limb Ischemia: Is Secondary Prevention a Key Intervention." Total funding will be $84,070.
Chenyu Lin of Cell Therapy has received an award from Sana Biotechnology, Inc. for a project entitled "A Phase 1 study evaluating SC262, a hypoimmune, allogeneic CD22-directed CAR T cell therapy, in relapsed and/or refractory Non-Hodgkins Lymphoma (VIVID)." Total funding will be $18,330.
Matthew McKinney of Cell Therapy has received an award from Lilly USA, LLC for a project entitled "Long-Term Safety of Pirtobrutinib in Participants from Study LOXO-BTK-18001 with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma." Total funding will be $60,020.
Jonathan Campbell of Endocrinology has received an award from Protagonist Therapeutics Inc. for a project entitled "Protagonist Research Agreement." Total funding will be $200,698.
Ara Metjian of Hematology has received an award from Takeda Development Center Americas, Inc for a project entitled "TAK-079-3002." Total funding will be $203,585.
Thomas Ortel of Hematology has received an award from Diagnostica Stago for a project entitled "sThemO 301 Analyzer." Total funding will be $69,842.
John Middleton of Nephrology has received an award from CSL Behring LLC for a project entitled "CSL Behring CSL300_2301 - a 2-part (phase 2b / 3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study.." Total funding will be $861,853.
Nicholas DeVito of Oncology has received an award from Astellas Pharma Global Development, Inc for a project entitled "A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator?s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (2138-CL-0102)." Total funding will be $1,129,512.
Nicholas DeVito of Oncology has received an award from Legend Biotech USA, Inc. for a project entitled "A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal." Total funding will be $615,663.
Vidhya Karivedu of Oncology has received an award from Regeneron Pharmaceuticals, Inc. for a project entitled "A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMABAND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA." Total funding will be $1,013,575.
Neal Ready of Oncology has received an award from Bristol-Myers Squibb Company for a project entitled "A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy." Total funding will be $485,965.
Thomas Stinchcombe of Oncology has received an award from Nuvalent, Inc. for a project entitled "Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)." Total funding will be $263,336.
Yuh Chin Huang of Pulmonary has received an award from United Therapeutics Corporation for a project entitled "Tyvaso COPD PII - Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia""." Total funding will be $311,536.
Lisa Criscione-Schreiber of Rheumatology has received an award from Allogene Therapeutics, Inc. for a project entitled "DRA02 - A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN AUTOIMMUNE DISEASE (RESOLUTION)." Total funding will be $1,013,890.